Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCNW3M)

Drug Name

2-hydroxylauric acid Drug Info

Synonyms

2-OH-C12; 2-hydroxy lauric acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Inflammation-related GPCR EX33 (GPR84)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PBI-4050	DMPXK27	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[3]
SHR0534	DMGFTAI	Type 2 diabetes	5A11	Phase 1	[4]
3-hydroxy capric acid	DMC70P1	Discovery agent	N.A.	Investigative	[2]
2-hydroxy capric acid	DMJAN52	Discovery agent	N.A.	Investigative	[2]
6-n-octylaminouracil	DMXJFCQ	Discovery agent	N.A.	Investigative	[2]
3-hydroxylauric acid	DMNMB6V	Discovery agent	N.A.	Investigative	[2]
undecanoic acid	DMFOIPL	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inflammation-related GPCR EX33 (GPR84)	TTG0MQD	GPR84_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5849).
2	Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91.
3	Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663.
4	Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.
5	Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem. 2006 Nov 10;281(45):34457-64.